Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:FOLD
- CUSIP: 03152W10
- Web: www.amicusrx.com
Capitalization:- Market Cap: $2.59685 billion
- Outstanding Shares: 164,566,000
Average Prices:- 50 Day Moving Avg: $13.24
- 200 Day Moving Avg: $9.90
- 52 Week Range: $4.41 - $15.70
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -16.05
- P/E Growth: -0.20
Sales & Book Value:- Annual Revenue: $16.28 million
- Price / Sales: 147.68
- Book Value: $1.86 per share
- Price / Book: 7.85
Profitability:- EBIDTA: ($186,930,000.00)
- Net Margins: -1,279.88%
- Return on Equity: -61.25%
- Return on Assets: -20.08%
Debt:- Debt-to-Equity Ratio: 0.60%
- Current Ratio: 2.39%
- Quick Ratio: 2.35%
Misc:- Average Volume: 3.93 million shs.
- Beta: 1.82
- Short Ratio: 6.74
Frequently Asked Questions for Amicus Therapeutics (NASDAQ:FOLD)
What is Amicus Therapeutics' stock symbol?
Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."
How were Amicus Therapeutics' earnings last quarter?
Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its quarterly earnings results on Monday, August, 7th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.03. The firm earned $7.16 million during the quarter, compared to the consensus estimate of $6.96 million. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. During the same period in the previous year, the firm posted ($0.40) earnings per share. View Amicus Therapeutics' Earnings History.
When will Amicus Therapeutics make its next earnings announcement?
Where is Amicus Therapeutics' stock going? Where will Amicus Therapeutics' stock price be in 2017?
6 brokerages have issued twelve-month price targets for Amicus Therapeutics' shares. Their forecasts range from $9.00 to $18.00. On average, they anticipate Amicus Therapeutics' share price to reach $15.08 in the next year. View Analyst Ratings for Amicus Therapeutics.
What are analysts saying about Amicus Therapeutics stock?
Here are some recent quotes from research analysts about Amicus Therapeutics stock:
- 1. According to Zacks Investment Research, "AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. " (7/19/2017)
- 2. Cowen and Company analysts commented, "This morning, FOLD announced that after more recent FDA talks and written." (7/11/2017)
Are investors shorting Amicus Therapeutics?
Amicus Therapeutics saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 33,782,444 shares, an increase of 1.2% from the August 15th total of 33,370,329 shares. Based on an average trading volume of 2,769,628 shares, the days-to-cover ratio is currently 12.2 days. Currently, 21.2% of the company's stock are sold short.
Who are some of Amicus Therapeutics' key competitors?
Some companies that are related to Amicus Therapeutics include Catalent (CTLT), Patheon NV (PTHN), Valeant Pharmaceuticals International (VRX), Taro Pharmaceutical Industries (TARO), Akorn (AKRX), Opko Health (OPK), Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Horizon Pharma PLC (HZNP), Corcept Therapeutics Incorporated (CORT), Theravance Biopharma (TBPH), Impax Laboratories (IPXL), Akcea Therapeutics (AKCA), Cambrex Corporation (CBM), Emergent Biosolutions (EBS), Innoviva (INVA), Pacira Pharmaceuticals (PCRX) and Amphastar Pharmaceuticals (AMPH).
Who are Amicus Therapeutics' key executives?
Amicus Therapeutics' management team includes the folowing people:
- John F. Crowley J.D., Chairman of the Board, Chief Executive Officer
- Bradley L. Campbell, President, Chief Operating Officer
- William D. Baird III, Chief Financial Officer
- Daphne E. Quimi, Senior Vice President - Finance and Administration, Corporate Controller
- Kurt J. W. Andrews, Senior Vice President - Human Resources
- Hung Viet Do, Chief Scientific Officer
- Ellen S. Rosenberg, General Counsel and Corporate Secretary
- Jay A. Barth M.D., Chief Medical Officer
- Donald J. Hayden Jr., Lead Independent Director
- Robert A. Essner, Independent Director
Who owns Amicus Therapeutics stock?
Amicus Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Redmile Group LLC (7.32%), BlackRock Inc. (8.24%), Vanguard Group Inc. (6.38%), Jennison Associates LLC (6.25%) and Palo Alto Investors LLC (4.83%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, Kenneth Peist, Life Sciences Maste Perceptive, Margaret G Mcglynn, Perceptive Advisors Llc and William D Baird III. View Institutional Ownership Trends for Amicus Therapeutics.
Who sold Amicus Therapeutics stock? Who is selling Amicus Therapeutics stock?
Amicus Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Grosvenor Capital Management L.P., Canada Pension Plan Investment Board, AXA, Sectoral Asset Management Inc, Victory Capital Management Inc., Tekla Capital Management LLC, Asymmetry Capital Management L.P. and BlackRock Inc.. Company insiders that have sold Amicus Therapeutics stock in the last year include Bradley L Campbell, Daphne Quimi, Hung Do and Jay Barth. View Insider Buying and Selling for Amicus Therapeutics.
Who bought Amicus Therapeutics stock? Who is buying Amicus Therapeutics stock?
Amicus Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Farallon Capital Management LLC, FMR LLC, Redmile Group LLC, Vanguard Group Inc., Balyasny Asset Management LLC, Emory University and Quantitative Investment Management LLC. Company insiders that have bought Amicus Therapeutics stock in the last two years include Ellen Rosenberg, Life Sciences Maste Perceptive, Margaret G Mcglynn and Perceptive Advisors Llc. View Insider Buying and Selling for Amicus Therapeutics.
How do I buy Amicus Therapeutics stock?
Shares of Amicus Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amicus Therapeutics' stock price today?
One share of Amicus Therapeutics stock can currently be purchased for approximately $14.61.
MarketBeat Community Rating for Amicus Therapeutics (NASDAQ FOLD)MarketBeat's community ratings are surveys of what our community members think about Amicus Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Amicus Therapeutics (NASDAQ:FOLD) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 6 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $15.08 (3.24% upside) |
Analysts' Ratings History for Amicus Therapeutics (NASDAQ:FOLD)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/16/2017 | Leerink Swann | Reiterated Rating | Outperform | $18.00 -> $17.00 | Low |  |
| 9/14/2017 | Cowen and Company | Reiterated Rating | Outperform | $16.00 -> $18.00 | Low | |
| 9/13/2017 | Chardan Capital | Reiterated Rating | Buy -> Buy | $17.50 -> $16.50 | Low | |
| 8/9/2017 | J P Morgan Chase & Co | Reiterated Rating | Overweight | $13.00 -> $15.00 | High | |
| 7/12/2017 | Robert W. Baird | Boost Price Target | Outperform | $12.00 -> $15.00 | Medium | |
| 5/25/2017 | Bank of America Corporation | Lower Price Target | Buy | $10.00 -> $9.00 | Medium | |
| 3/30/2016 | Goldman Sachs Group, Inc. (The) | Initiated Coverage | Neutral | $10.00 | N/A | |
| 3/8/2016 | Janney Montgomery Scott | Upgrade | Neutral -> Buy | $10.00 -> $12.00 | N/A | |
(Data available from 9/23/2015 forward)
Earnings History for Amicus Therapeutics (NASDAQ:FOLD)Earnings History by Quarter for Amicus Therapeutics (NASDAQ FOLD)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | ($0.37) | | | | | N/A | |
| 8/7/2017 | Q2 2017 | ($0.37) | ($0.34) | $6.96 million | $7.16 million | View | Listen | |
| 5/9/2017 | Q1 2017 | ($0.37) | ($0.39) | $4.16 million | $4.20 million | View | Listen | |
| 3/1/2017 | Q4 2016 | ($0.33) | ($0.32) | $3.16 million | $2.83 million | View | Listen | |
| 11/7/2016 | Q3 | ($0.31) | ($0.33) | $1.71 million | $2.10 million | View | Listen | |
| 8/9/2016 | Q2 | ($0.33) | ($0.40) | $0.17 million | | View | N/A | |
| 5/3/2016 | Q1 | ($0.34) | ($0.35) | | | View | Listen | |
| 11/3/2015 | Q3 | ($0.25) | ($0.32) | | | View | N/A | |
| 8/5/2015 | Q215 | ($0.24) | ($0.26) | | | View | N/A | |
| 5/5/2015 | Q115 | ($0.14) | ($0.25) | $0.50 million | | View | N/A | |
| 3/3/2015 | Q414 | ($0.18) | ($0.24) | $0.48 million | | View | N/A | |
| 11/6/2014 | Q3 2014 | ($0.21) | ($0.22) | $1.00 million | $0.29 million | View | N/A | |
| 8/7/2014 | Q2 2014 | ($0.24) | ($0.23) | | $0.48 million | View | N/A | |
| 5/5/2014 | Q1 2014 | ($0.23) | ($0.25) | $0.20 million | $0.46 million | View | N/A | |
| 3/3/2014 | Q4 13 | ($0.32) | ($0.22) | | $0.32 million | View | N/A | |
| 11/11/2013 | Q3 | ($0.32) | ($0.29) | | | View | N/A | |
| 8/7/2013 | Q2 2013 | ($0.35) | ($0.31) | | | View | N/A | |
| 5/9/2013 | Q1 2013 | ($0.30) | ($0.34) | | | View | N/A | |
| 11/5/2012 | Q312 | ($0.24) | ($0.31) | $8.82 million | $5.80 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Amicus Therapeutics (NASDAQ:FOLD)2017 EPS Consensus Estimate: ($1.34)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.39) | ($0.39) | ($0.39) |
| Q2 2017 | 1 | ($0.35) | ($0.35) | ($0.35) |
| Q3 2017 | 1 | ($0.30) | ($0.30) | ($0.30) |
| Q4 2017 | 1 | ($0.30) | ($0.30) | ($0.30) |
(Data provided by Zacks Investment Research)
Dividend History for Amicus Therapeutics (NASDAQ:FOLD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Amicus Therapeutics (NASDAQ:FOLD)Insider Ownership Percentage: 3.40%
Insider Trades by Quarter for Amicus Therapeutics (NASDAQ:FOLD)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/13/2017 | Life Sciences Maste Perceptive | Major Shareholder | Buy | 1,500,000 | $12.25 | $18,375,000.00 | |
| 6/19/2017 | Jay Barth | Insider | Sell | 30,000 | $10.00 | $300,000.00 | |
| 5/19/2017 | Hung Do | Insider | Sell | 29,914 | $8.00 | $239,312.00 | |
| 3/2/2017 | Bradley L Campbell | COO | Sell | 49,050 | $8.00 | $392,400.00 | |
| 1/13/2017 | Hung Do | Insider | Sell | 25,000 | $6.00 | $150,000.00 | |
| 12/30/2016 | Perceptive Advisors Llc | Major Shareholder | Buy | 94,750 | $4.96 | $469,960.00 | |
| 12/29/2016 | Perceptive Advisors Llc | Major Shareholder | Buy | 142,125 | $4.87 | $692,148.75 | |
| 12/23/2016 | Perceptive Advisors Llc | Major Shareholder | Buy | 85,275 | $4.81 | $410,172.75 | |
| 12/22/2016 | Perceptive Advisors Llc | Major Shareholder | Buy | 189,500 | $4.51 | $854,645.00 | |
| 11/9/2016 | Daphne Quimi | SVP | Sell | 8,546 | $8.00 | $68,368.00 | |
| 11/1/2016 | Hung Do | Insider | Sell | 25,000 | $7.00 | $175,000.00 | |
| 10/3/2016 | Hung Do | Insider | Sell | 25,000 | $7.25 | $181,250.00 | |
| 9/20/2016 | William D Baird III | CFO | Sell | 20,500 | $8.00 | $164,000.00 | |
| 9/6/2016 | Hung Do | Insider | Sell | 25,000 | $7.00 | $175,000.00 | |
| 8/25/2016 | Perceptive Advisors Llc | Insider | Sell | 1,100,000 | $6.81 | $7,491,000.00 | |
| 8/4/2016 | Jay Barth | Insider | Sell | 10,458 | $7.00 | $73,206.00 | |
| 7/27/2016 | Jay Barth | Insider | Sell | 20,916 | $7.00 | $146,412.00 | |
| 6/2/2016 | Ellen Rosenberg | General Counsel | Buy | 15,000 | $7.67 | $115,050.00 | |
| 11/10/2015 | Margaret G Mcglynn | Director | Buy | 10,000 | $10.27 | $102,700.00 | |
| 10/7/2015 | Perceptive Advisors Llc | Major Shareholder | Buy | 50,000 | $6.27 | $313,500.00 | |
| 10/6/2015 | Perceptive Advisors Llc | Major Shareholder | Buy | 750,000 | $6.71 | $5,032,500.00 | |
| 10/1/2015 | Kenneth Peist | VP | Sell | 10,000 | $13.14 | $131,400.00 | |
| 9/21/2015 | Bradley L. Campbell | COO | Sell | 13,001 | $16.78 | $218,156.78 | |
| 9/21/2015 | William D. Baird III | CFO | Sell | 15,236 | $16.78 | $255,660.08 | |
| 9/15/2015 | Hung Do | Insider | Sell | 25,000 | $17.75 | $443,750.00 | |
| 9/14/2015 | Daphne Quimi | VP | Sell | 2,500 | $18.08 | $45,200.00 | |
| 7/16/2015 | John F Crowley | CEO | Sell | 16,025 | $16.00 | $256,400.00 | |
| 7/14/2015 | John F Crowley | CEO | Sell | 142,250 | $15.03 | $2,138,017.50 | |
| 7/13/2015 | Glenn Sblendorio | Director | Sell | 10,000 | $15.00 | $150,000.00 | |
| 7/13/2015 | John F Crowley | CEO | Sell | 7,750 | $15.01 | $116,327.50 | |
| 7/13/2015 | Ken Valenzano | SVP | Sell | 15,000 | $15.00 | $225,000.00 | |
| 7/8/2015 | Dipal Doshi | SVP | Sell | 6,250 | $13.87 | $86,687.50 | |
| 7/1/2015 | Jayne Gershkowitz | SVP | Sell | 10,649 | $13.97 | $148,766.53 | |
| 7/1/2015 | Kenneth Peist | VP | Sell | 10,000 | $13.98 | $139,800.00 | |
| 6/23/2015 | Donald J Hayden Jr | Director | Sell | 55,000 | $14.01 | $770,550.00 | |
| 6/22/2015 | Jeff Castelli | SVP | Sell | 18,981 | $13.94 | $264,595.14 | |
| 6/19/2015 | Bradley L Campbell | COO | Sell | 13,000 | $13.26 | $172,380.00 | |
| 6/19/2015 | Enrique Dilone | SVP | Sell | 14,045 | $13.26 | $186,236.70 | |
| 6/19/2015 | William D Baird III | CFO | Sell | 15,235 | $13.26 | $202,016.10 | |
| 6/15/2015 | Jeff Castelli | SVP | Sell | 7,377 | $14.17 | $104,532.09 | |
| 6/15/2015 | Julie Yu | VP | Sell | 8,195 | $14.17 | $116,123.15 | |
| 6/8/2015 | Jeff Castelli | SVP | Sell | 17,312 | $12.87 | $222,805.44 | |
| 6/8/2015 | John F Crowley | CEO | Sell | 55,000 | $13.01 | $715,550.00 | |
| 5/11/2015 | Jeff Castelli | SVP | Sell | 10,000 | $10.84 | $108,400.00 | |
| 5/11/2015 | Kenneth Peist | VP | Sell | 12,500 | $10.84 | $135,500.00 | |
| 5/11/2015 | William D Baird III | CFO | Sell | 24,800 | $10.84 | $268,832.00 | |
| 4/15/2015 | Glenn Sblendorio | Director | Sell | 20,000 | $12.50 | $250,000.00 | |
| 4/15/2015 | Ken Valenzano | VP | Sell | 5,000 | $12.50 | $62,500.00 | |
| 4/10/2015 | John F Crowley | CEO | Sell | 11,678 | $12.00 | $140,136.00 | |
| 4/1/2015 | Jeff Castelli | VP | Sell | 9,489 | $10.69 | $101,437.41 | |
| 1/5/2015 | Jeff Castelli | VP | Sell | 4,667 | $9.00 | $42,003.00 | |
| 12/4/2014 | John F Crowley | CEO | Sell | 89,000 | $8.36 | $744,040.00 | |
| 11/25/2014 | Bradley L Campbell | COO | Sell | 7,250 | $8.00 | $58,000.00 | |
| 11/25/2014 | Jeff Castelli | VP | Sell | 8,103 | $8.00 | $64,824.00 | |
| 11/25/2014 | William D Baird III | CFO | Sell | 10,000 | $8.00 | $80,000.00 | |
| 11/19/2014 | Perceptive Advisors Llc | Major Shareholder | Buy | 2,100,000 | $6.50 | $13,650,000.00 | |
| 10/27/2014 | Plc Glaxosmithkline | Major Shareholder | Sell | 11,315,825 | $5.29 | $59,860,714.25 | |
| 10/3/2014 | Jeff Castelli | VP | Sell | 8,552 | $7.00 | $59,864.00 | |
| 10/3/2014 | William D Baird III | CFO | Sell | 10,000 | $7.00 | $70,000.00 | |
| 10/2/2014 | Julie Yu | VP | Sell | 4,759 | $5.99 | $28,506.41 | |
| 9/29/2014 | Daphne Quimi | VP | Sell | 10,738 | $6.10 | $65,501.80 | |
| 9/29/2014 | William D Baird III | CFO | Sell | 25,311 | $6.09 | $154,143.99 | |
| 8/27/2014 | Glenn Sblendorio | Director | Sell | 10,000 | $6.50 | $65,000.00 | |
| 8/27/2014 | Jayne Gershkowitz | VP | Sell | 5,000 | $7.00 | $35,000.00 | |
| 8/25/2014 | Bradley L Campbell | COO | Sell | 7,000 | $6.00 | $42,000.00 | |
| 8/25/2014 | Jayne Gershkowitz | VP | Sell | 5,000 | $6.00 | $30,000.00 | |
| 8/20/2014 | Bradley L Campbell | COO | Sell | 18,750 | $5.40 | $101,250.00 | |
| 8/20/2014 | Enrique Dilone | VP | Sell | 12,810 | $5.40 | $69,174.00 | |
| 6/30/2014 | Perceptive Advisors Llc | Major Shareholder | Buy | 4,000,000 | $3.50 | $14,000,000.00 | |
| 11/20/2013 | Plc Glaxosmithkline | major shareholder | Buy | 1,500,000 | $2.00 | $3,000,000.00 | |
| 3/15/2013 | Sol J Barer | Director | Buy | 25,000 | $3.40 | $85,000.00 | |
| 11/13/2012 | Joan Winterbottom | SVP | Buy | 1,665 | $4.54 | $7,559.10 | |
(Data available from 1/1/2013 forward)
Headline Trends for Amicus Therapeutics (NASDAQ:FOLD)
Latest Headlines for Amicus Therapeutics (NASDAQ:FOLD)
| Source: |
|
| Date | Headline |
|---|
 | U.S. FDA Grants Orphan Drug Designation for ATB200/AT2221 for Pompe Disease
finance.yahoo.com - September 22 at 8:08 AM |
 | Amicus Therapeutics (FOLD) Says it Was Granted FDA Orphan Drug Designation for ATB200/AT2221 for Pompe Disease - StreetInsider.com
www.streetinsider.com - September 21 at 6:53 PM |
 | Amicus Therapeutics' ATB200/AT2221 an Orphan Drug in U.S. for Pompe disease; shares ahead 2% premarket
seekingalpha.com - September 21 at 8:54 AM |
| Amicus Therapeutics (FOLD) Granted Fast Track Designation for Migalastat for Treatment of Fabry Disease - StreetInsider.com
www.streetinsider.com - September 21 at 8:26 AM |
| Harry Boxer’s five stocks to watch today
finance.yahoo.com - September 20 at 7:44 PM |
| Amicus Therapeutics to Present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
finance.yahoo.com - September 20 at 7:44 PM |
| Amicus Therapeutics (FOLD) Granted Fast Track Designation for Migalastat for Treatment of Fabry Disease
www.streetinsider.com - September 19 at 6:45 PM |
| U.S. FDA Grants Fast Track Designation for Amicus Therapeutics’ Migalastat for Treatment of Fabry Disease
finance.yahoo.com - September 19 at 6:45 PM |
| [$$] Clinical Development News, Sept. 11-15
finance.yahoo.com - September 18 at 4:05 AM |
| Amicus Therapeutics (FOLD) Reports Health Canada Approval for Galafold for Treatment of Fabry Disease
www.streetinsider.com - September 16 at 6:08 PM |
 | Amicus Therapeutics, Inc. (FOLD) Stock Rating Reaffirmed by Leerink Swann
www.americanbankingnews.com - September 16 at 9:50 AM |
| Leerink Swann Comments on Amicus Therapeutics, Inc.'s Q3 2017 Earnings (FOLD)
www.americanbankingnews.com - September 15 at 8:02 AM |
| Amicus Therapeutics Announces Approval for Galafold™ (Migalastat) for Treatment of Fabry Disease in Canada
finance.yahoo.com - September 14 at 7:23 PM |
| Cowen and Company Reiterates "Outperform" Rating for Amicus Therapeutics, Inc. (FOLD)
www.americanbankingnews.com - September 14 at 1:04 PM |
 | Amicus: Phase 3 SD-101 Study Fails To Meet Primary Endpoints - Quick Facts
www.rttnews.com - September 13 at 8:15 PM |
| Amicus Therapeutics Announces Top-Line Phase 3 Results for SD-101 in Epidermolysis Bullosa
finance.yahoo.com - September 13 at 8:15 PM |
| A father's fight to find a cure for his children's rare disease
finance.yahoo.com - September 13 at 8:15 PM |
| Amicus abandons wound treatment, focus shifts to future trial data
finance.yahoo.com - September 13 at 8:15 PM |
| Amicus Therapeutics, Inc. (FOLD) Price Target Cut to $16.50 by Analysts at Chardan Capital
www.americanbankingnews.com - September 13 at 5:30 PM |
| Amicus Therapeutics' SD-101 flunks late-stage study in epidermolysis bullosa; shares down 13% premarket
seekingalpha.com - September 13 at 7:31 AM |
| Zacks: Brokerages Anticipate Amicus Therapeutics, Inc. (FOLD) Will Announce Quarterly Sales of $9.93 Million
www.americanbankingnews.com - September 13 at 5:52 AM |
 | Options Traders Expect Huge Moves in Amicus Therapeutics (FOLD) Stock - Nasdaq
www.nasdaq.com - September 13 at 5:39 AM |
| Options Traders Expect Huge Moves in Amicus Therapeutics (FOLD) Stock
finance.yahoo.com - September 12 at 7:35 PM |
 | Is Amicus Therapeutics Stock Still a Strong Buy?
www.fool.com - September 10 at 8:37 AM |
| Critical Contrast: Amicus Therapeutics (FOLD) versus its Peers
www.americanbankingnews.com - September 9 at 10:32 PM |
| Time to Bring Amicus Therapeutics Into the 'FOLD'
finance.yahoo.com - September 8 at 7:12 PM |
| Amicus Therapeutics, Inc. (FOLD) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 2 at 4:40 AM |
| Brokerages Expect Amicus Therapeutics, Inc. (FOLD) Will Post Quarterly Sales of $9.93 Million
www.americanbankingnews.com - August 26 at 6:48 PM |
 | Amicus Therapeutics to Highlight Fabry Disease Program at the 13th International Congress of Inborn Errors of ... - GlobeNewswire (press release)
globenewswire.com - August 26 at 1:25 AM |
| Amicus Therapeutics to Highlight Fabry Disease Program at the 13th International Congress of Inborn Errors of Metabolism (ICIEM)
finance.yahoo.com - August 26 at 1:25 AM |
| Analysts Expect Amicus Therapeutics, Inc. (FOLD) Will Post Earnings of -$0.39 Per Share
www.americanbankingnews.com - August 24 at 2:06 AM |
| Today's Research Reports on Stocks to Watch: Amicus Therapeutics Inc. and Ritter Pharmaceuticals Inc.
finance.yahoo.com - August 21 at 6:13 PM |
| [$$] Clinical Development News, Aug. 14-18
finance.yahoo.com - August 20 at 10:22 PM |
| Amicus Therapeutics, Inc. (FOLD) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - August 20 at 1:14 PM |
| Upcoming Events - Late-Stage Data Due For Amicus And Insmed - Seeking Alpha
seekingalpha.com - August 18 at 6:39 PM |
| Amicus Therapeutics (FOLD) Receives Approval for Galafold for ... - StreetInsider.com
www.streetinsider.com - August 17 at 4:53 AM |
| Amicus Therapeutics (FOLD) Receives Approval for Galafold for Treatment of Fabry Disease in Australia
www.streetinsider.com - August 16 at 5:28 AM |
| Amicus Therapeutics Announces Approval for Galafold™ (Migalastat) for Treatment of Fabry Disease in Australia
finance.yahoo.com - August 15 at 7:24 PM |
| Cowen and Company Reiterates Buy Rating for Amicus Therapeutics, Inc. (NASDAQ:FOLD)
www.americanbankingnews.com - August 14 at 4:18 PM |
| Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - August 13 at 11:58 AM |
| Amicus Therapeutics, Inc. (NASDAQ:FOLD) Short Interest Down 4.4% in July
www.americanbankingnews.com - August 12 at 3:08 AM |
| Amicus Therapeutics Sees Unusually Large Options Volume (NASDAQ:FOLD)
www.americanbankingnews.com - August 10 at 8:06 AM |
| Amicus Therapeutics, Inc. (FOLD) Earns Overweight Rating from J P Morgan Chase & Co
www.americanbankingnews.com - August 10 at 12:58 AM |
| The Sole Reason Amicus Therapeutics, Inc. Exploded 29% Higher in July - Motley Fool
www.fool.com - August 9 at 6:55 PM |
| The Sole Reason Amicus Therapeutics, Inc. Exploded 29% Higher in July
www.fool.com - August 9 at 3:35 PM |
| Q3 2017 EPS Estimates for Amicus Therapeutics, Inc. Lifted by Leerink Swann (NASDAQ:FOLD)
www.americanbankingnews.com - August 9 at 8:08 AM |
| Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 8 at 7:46 AM |
| Edited Transcript of FOLD earnings conference call or presentation 7-Aug-17 12:30pm GMT
finance.yahoo.com - August 7 at 9:15 PM |
| Amicus Therapeutics' (FOLD) CEO John Crowley on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 7 at 4:15 PM |
| Amicus Therapeutics Announces Second Quarter 2017 Financial Results and Corporate Updates
finance.yahoo.com - August 7 at 4:15 PM |
Amicus Therapeutics (FOLD) Chart for Saturday, September, 23, 2017
